NCT05068947View on ClinicalTrials.gov

Safety, Tolerability, and Pharmacokinetic Study of Single Ascending Dose of GV101 in Healthy Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

16

Participants

Timeline

Start Date

September 10, 2021

Primary Completion Date

October 22, 2021

Study Completion Date

October 22, 2021

Conditions
Phase 1
Interventions
DRUG

GV101

GV101 administered once orally.

DRUG

Placebo

Matched placebo

Trial Locations (1)

33014

Clinical Pharmacology of Miami, Hialeah

Sponsors
All Listed Sponsors
lead

Graviton Bioscience Corporation

INDUSTRY